{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:11:07Z","timestamp":1791875467745,"version":"4.3.4"},"reference-count":48,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: \u201cOzempic face\u201d is an aesthetic side effect associated with the use of the antidiabetic agent Ozempic (semaglutide), characterized by a prematurely aged and fatigued facial appearance due to rapid weight loss. Currently, treatment options for this condition are limited. In this study, we present our clinical experience with the BodyTite device, provided by InMode Italy S.r.l. (Rome, Italy). Materials and Methods: We report a case series involving 24 patients (19 women and 5 men, aged 27\u201365 years), treated with subdermal bipolar radiofrequency (Endotissutal Bipolar Radiofrequency) between 2023 and 2024. All patients underwent a minimum follow-up of 12 months. At the end of the follow-up period, patients rated their satisfaction on a from 0 to 10 scale, and an independent expert assessed the stability of clinical outcomes. Results: The majority of patients reported high satisfaction levels (\u22658), which correlated with the independent expert\u2019s evaluation of treatment efficacy and result stability. The only observed adverse event was transient cutaneous erythema. Conclusions: \u201cOzempic face\u201d is an increasingly common side effect associated with newer classes of antidiabetic medications. Although these drugs offer significant metabolic benefits, the accompanying facial volume loss and aging are often poorly tolerated by patients. Our findings suggest that subdermal bipolar radiofrequency represents a safe, low-risk, and cost-effective therapeutic option for the aesthetic management of Ozempic face.<\/jats:p>","DOI":"10.3390\/jcm14155269","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T12:56:43Z","timestamp":1753448203000},"page":"5269","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["\u201cOzempic Face\u201d: An Emerging Drug-Related Aesthetic Concern and Its Treatment with Endotissutal Bipolar Radiofrequency (RF)\u2014Our Experience"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-9000","authenticated-orcid":false,"given":"Luciano","family":"Catalfamo","sequence":"first","affiliation":[{"name":"Department of Biomedical, Dental and Morphological and Functional Imaging (BIOMORF), University of Messina, Via Consolare Valeria 1, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Saverio","family":"De Ponte","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Dental and Morphological and Functional Imaging (BIOMORF), University of Messina, Via Consolare Valeria 1, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8757-7600","authenticated-orcid":false,"given":"Danilo","family":"De Rinaldis","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Dental and Morphological and Functional Imaging (BIOMORF), University of Messina, Via Consolare Valeria 1, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: Systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00592-023-02154-4","article-title":"Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: A systematic review and meta-analysis","volume":"60","author":"Diallo","year":"2023","journal-title":"Acta Diabetol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: A meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., and LeRoith, D. (2023). Glucagon-like peptide-1: A multi-faceted anti-inflammatory agent. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1148209"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Popoviciu, M.S., P\u0103duraru, L., Yahya, G., Metwally, K., and Cavalu, S. (2023). Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310449"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: Mechanisms, management, and future directions","volume":"9","author":"Jalleh","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1159\/000521264","article-title":"Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity","volume":"96","author":"Jensterle","year":"2023","journal-title":"Horm. Res. Paediatr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101098","DOI":"10.1016\/j.lanepe.2024.101098","article-title":"Why are we still in need for novel anti-obesity medications?","volume":"47","author":"Novikoff","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Saran, A., Raisinghani, R., Paliwal, S., and Sharma, S. (Mol. Divers., 2025). GLP-1R agonists: Recent advances, current gaps, and future challenges, Mol. Divers., Epub ahead of print.","DOI":"10.1007\/s11030-025-11195-6"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Forzano, I., Varzideh, F., Avvisato, R., Jankauskas, S.S., Mone, P., and Santulli, G. (2022). Tirzepatide: A Systematic Update. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314631"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1567201818666210614100603","article-title":"Assessment of Exenatide loaded Biotinylated Trimethylated Chitosan\/HP- 55 Nanoparticles","volume":"19","author":"Guo","year":"2022","journal-title":"Curr. Drug Deliv."},{"key":"ref_18","unstructured":"Cerillo, J.L., and Parmar, M. (2025). Liraglutide. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1111\/dom.15258","article-title":"Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study)","volume":"25","author":"Kimura","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40265-013-0033-3","article-title":"Lixisenatide: First global approval","volume":"73","author":"Elkinson","year":"2013","journal-title":"Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Smits, M.M., and Van Raalte, D.H. (2021). Safety of Semaglutide. Front. Endocrinol., 12, Erratum in Front. Endocrinol. 2021, 12, 786732.","DOI":"10.3389\/fendo.2021.645563"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: A pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of Subcutaneous Semaglutide vs. Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/dom.15318","article-title":"Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis","volume":"26","author":"Hankosky","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2174\/1573399816666200705210006","article-title":"Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus","volume":"17","author":"Ida","year":"2021","journal-title":"Curr. Diabetes Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e70080","DOI":"10.1002\/prp2.70080","article-title":"Analysis of Reporting Trends of Serious Adverse Events Associated with Anti-Obesity Drugs","volume":"13","year":"2025","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7570\/jomes21033","article-title":"Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?","volume":"30","author":"Ryan","year":"2021","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., Ajabiya, J., Teli, D., Bojarska, J., and Apostolopoulos, V. (2022). Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules, 27, Erratum in Molecules 2025, 30, 1190.","DOI":"10.3390\/molecules30061190"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e012732","DOI":"10.1161\/CIRCEP.124.012732","article-title":"Characterization and Clinical Significance of Hemolysis After Pulsed Field Ablation for Atrial Fibrillation: Results of a Multicenter Analysis","volume":"17","author":"Popa","year":"2024","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103680","DOI":"10.1016\/j.amsu.2022.103680","article-title":"Ultrasound-guided monopolar versus bipolar radiofrequency ablation for genicular nerves in chronic knee osteoarthritis pain: A randomized controlled study","volume":"77","author":"Elemam","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/DSS.0000000000003666","article-title":"Noninvasive Hands-free Bipolar Radiofrequency Facial Remodeling Device for the Improvement of Skin Appearance","volume":"49","author":"Labadie","year":"2023","journal-title":"Dermatol. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000328284","article-title":"Skin tightening","volume":"42","author":"Kammer","year":"2011","journal-title":"Curr. Probl. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kreindel, M., and Mulholland, S. (2022). The Basic Science of Radiofrequency-Based Devices. Enhanced Liposuction\u2014New Perspectives and Techniques, IntechOpen.","DOI":"10.5772\/intechopen.96652"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e13422","DOI":"10.1111\/srt.13422","article-title":"Evaluation of short-term face rejuvenation effects of non-ablative bipolar radiofrequency treatment performed by Med-RF\u00a9 device","volume":"29","author":"Palmieri","year":"2023","journal-title":"Skin Res. Technol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/SCS.0000000000008925","article-title":"The Application of Subcutaneous Radiofrequency After Liposuction for the Lower Face and Neck Contouring Under Local Anesthesia","volume":"34","author":"Zhu","year":"2023","journal-title":"J. Craniofac. Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1055\/a-2148-6321","article-title":"Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons","volume":"39","author":"Humphrey","year":"2023","journal-title":"Facial Plast. Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1093\/asj\/sjz055","article-title":"Adjustable Depth Fractional Radiofrequency Combined With Bipolar Radiofrequency: A Minimally Invasive Combination Treatment for Skin Laxity","volume":"39","author":"Dayan","year":"2019","journal-title":"Aesthet. Surg. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/PRS.0000000000009535","article-title":"Minimally Invasive Approach to Skin Tightening of the Face and Body: Systematic Review of Monopolar and Bipolar Radiofrequency Devices","volume":"150","author":"Rohrich","year":"2022","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_41","first-page":"176","article-title":"Experimental Study of Skin Contraction Induced by Bipolar Radiofrequency","volume":"30","author":"Liu","year":"2024","journal-title":"Altern. Ther. Health Med."},{"key":"ref_42","first-page":"22","article-title":"Comparing the Efficacy of Monopolar and Bipolar Radiofrequency Treatment on Facial Skin in Women","volume":"15","author":"Stochaj","year":"2022","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.fsc.2017.12.003","article-title":"Radiofrequency Technology in Face and Neck Rejuvenation","volume":"26","author":"Gentile","year":"2018","journal-title":"Facial Plast. Surg. Clin. N. Am."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/lsm.20731","article-title":"Bipolar fractional radiofrequency treatment induces neoelastogenesis and neocollagenesis","volume":"41","author":"Hantash","year":"2009","journal-title":"Lasers Surg. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/dsu.12065","article-title":"Prospective multicenter clinical trial of a minimally invasive temperature-controlled bipolar fractional radiofrequency system for rhytid and laxity treatment","volume":"39","author":"Newman","year":"2013","journal-title":"Dermatol. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s10103-021-03329-7","article-title":"Efficacy of fractional laser, radiofrequency and IPL rejuvenation of periorbital region","volume":"37","author":"Rotsztejn","year":"2022","journal-title":"Lasers Med. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/jocd.14400","article-title":"Bipolar fractionated radiofrequency midface lift: A retrospective review","volume":"21","author":"Martin","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.fsc.2007.01.004","article-title":"Bipolar radiofrequency for facial rejuvenation","volume":"15","author":"Sadick","year":"2007","journal-title":"Facial Plast. Surg. Clin. N. Am."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5269\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:16:05Z","timestamp":1760033765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":48,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jcm14155269"],"URL":"https:\/\/doi.org\/10.3390\/jcm14155269","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}